All In Biotech

NDA 218585 · Lenz Therap

Vizz

Aceclidine Hydrochloride · Ophthalmic

Novel

CDER novel approval, Jul 31, 2025: To treat presbyopia

Last checked: Nov 20, 2026Latest source record: Jul 31, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2025

Jul 31, 2025

Approved uses

1

Original approval plus efficacy supplements

Registered trials

10

4 Phase 3, 0 recruiting

FAERS reports

735

34 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 14, 2026.

VIZZ is indicated for the treatment of presbyopia in adults. VIZZ is a cholinergic agonist indicated for the treatment of presbyopia in adults ( 1 ).

Mechanism: Aceclidine is a cholinergic muscarinic agonist that stimulates muscarinic receptors located on smooth muscles. VIZZ is a predominantly pupil selective miotic that interacts with the iris with minimal ciliary muscle stimulation. VIZZ causes contraction of the iris sphincter muscle, resulting in a pinhole effect that extends depth of focus to improve vision.

Therapeutic areas: Ophthalmology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 31, 2025 Original approval · Type 1 - New Molecular Entity NovelLetterLabelReview
1 products under this application
  • VIZZ · ACECLIDINE HYDROCHLORIDE EQ 1.44% BASE · SOLUTION/DROPS, OPHTHALMIC · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Aceclidine" as an intervention, any sponsor and status, largest first.

All 10 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • ocular hyperaemia310
  • visual impairment248
  • instillation site irritation240
  • headache167
  • vision blurred102
  • drug ineffective100
  • drug effect less than expected76
  • vitreous floaters43
  • nausea34
  • off label use33
  • dizziness27
  • condition aggravated17

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20161
20211
2025173
2026560

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3 on PubMed

Sponsor: Lenz Therap

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.